315 related articles for article (PubMed ID: 23362325)
1. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
2. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
[TBL] [Abstract][Full Text] [Related]
3. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
[TBL] [Abstract][Full Text] [Related]
4. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
6. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
[TBL] [Abstract][Full Text] [Related]
7. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Abou-Alfa GK; Yen CJ; Hsu CH; O'Donoghue J; Beylergil V; Ruan S; Pandit-Taskar N; Gansukh B; Lyashchenko SK; Ma J; Wan P; Shao YY; Lin ZZ; Frenette C; O'Neil B; Schwartz L; Smith-Jones PM; Ohtomo T; Tanaka T; Morikawa H; Maki Y; Ohishi N; Chen YC; Agajanov T; Boisserie F; Di Laurenzio L; Lee R; Larson SM; Cheng AL; Carrasquilo JA
Cancer Chemother Pharmacol; 2017 Feb; 79(2):421-429. PubMed ID: 28120036
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 antibodies: a new therapeutic target for liver cancer.
Feng M; Ho M
FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
Yorita K; Takahashi N; Takai H; Kato A; Suzuki M; Ishiguro T; Ohtomo T; Nagaike K; Kondo K; Chijiiwa K; Kataoka H
Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
Goyal L; Supko JG; Berlin J; Blaszkowsky LS; Carpenter A; Heuman DM; Hilderbrand SL; Stuart KE; Cotler S; Senzer NN; Chan E; Berg CL; Clark JW; Hezel AF; Ryan DP; Zhu AX
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1305-14. PubMed ID: 24121453
[TBL] [Abstract][Full Text] [Related]
17. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
[TBL] [Abstract][Full Text] [Related]
19. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
Sawada Y; Nakatsura T
Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
[TBL] [Abstract][Full Text] [Related]
20. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]